This study presents a potentially valuable exploration of the role of thalamic nuclei in language processing. The results will be of interest to researchers interested in the neurobiology of language.
Hosted on MSN
Roswell & new signals from space
With news of radio signals from distant galaxies, a government agency that wants to investigate extra-terrestrial life, and the 66th anniversary of the Roswell Incident, this week has felt like a '90s ...
Money transfer providers are increasingly diversifying their product ranges. For years, money transfer providers sought to do one thing: fulfil the need for faster, more cost-efficient cross-border ...
NEW YORK, NY / ACCESS Newswire / February 6, 2026 / Capital becomes meaningful only when it alters how a company behaves. Until then, it's just potential, visible but inactive. What matters is whether ...
As the devices continue to gain popularity, experts say it is important to understand what they can and cannot tell you, and how their data should be used. Your watch says you had three hours of deep ...
A flurry of posts from the White House, Department of Labor and Department of Homeland Security have included images, slogans and even a song used by the white nationalist right. In the past month, ...
The 16 teams who have qualified for the Champions League knockout phase play-off draw will find out their opponents on Friday. Proceedings start in Switzerland at 11:00 GMT and will involve the teams ...
Bitcoin has experienced a decline of 25% over the past six months and is currently trading below $88,000. This drop is attributed to macroeconomic uncertainties, risk-off sentiment, and diminishing ...
France to ditch US platforms Microsoft Teams, Zoom for ‘sovereign platform’ citing security concerns
France will replace the American platforms Microsoft Teams and Zoom with its own domestically developed video conferencing platform, which will be used in all government departments by 2027, the ...
Hosted on MSN
Roivant signals multiple pivotal trial readouts and accelerates brepocitinib phase III launch in 2026
CEO Matthew Gline opened the call highlighting "positive Phase II results for brepocitinib and cutaneous sarcoidosis and Roivant's financial results for the third quarter ended December 31, 2025." He ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results